FR22C1032I2 - Compositions anti-cgrp et leur utilisation - Google Patents

Compositions anti-cgrp et leur utilisation

Info

Publication number
FR22C1032I2
FR22C1032I2 FR22C1032C FR22C1032C FR22C1032I2 FR 22C1032 I2 FR22C1032 I2 FR 22C1032I2 FR 22C1032 C FR22C1032 C FR 22C1032C FR 22C1032 C FR22C1032 C FR 22C1032C FR 22C1032 I2 FR22C1032 I2 FR 22C1032I2
Authority
FR
France
Prior art keywords
cgrp compositions
cgrp
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1032C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1032(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of FR22C1032I1 publication Critical patent/FR22C1032I1/fr
Application granted granted Critical
Publication of FR22C1032I2 publication Critical patent/FR22C1032I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
FR22C1032C 2011-05-20 2022-06-29 Compositions anti-cgrp et leur utilisation Active FR22C1032I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20
EP12789693.4A EP2710039B1 (fr) 2011-05-20 2012-05-21 Compositions comprenant des anticorps anti-cgrp et leur utilisation
PCT/US2012/038844 WO2012162243A2 (fr) 2011-05-20 2012-05-21 Compositions comprenant des anticorps anti-cgrp et leur utilisation

Publications (2)

Publication Number Publication Date
FR22C1032I1 FR22C1032I1 (fr) 2022-09-09
FR22C1032I2 true FR22C1032I2 (fr) 2023-06-02

Family

ID=47175055

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1032C Active FR22C1032I2 (fr) 2011-05-20 2022-06-29 Compositions anti-cgrp et leur utilisation

Country Status (35)

Country Link
US (9) US9745373B2 (fr)
EP (5) EP2710039B1 (fr)
JP (3) JP6282584B2 (fr)
KR (1) KR102128627B1 (fr)
CN (5) CN107602700B (fr)
AP (1) AP2013007259A0 (fr)
AR (3) AR086516A1 (fr)
AU (3) AU2012258966C1 (fr)
BR (2) BR112013029932A2 (fr)
CA (3) CA3079978A1 (fr)
CL (3) CL2013003336A1 (fr)
CO (1) CO6870005A2 (fr)
CY (2) CY1124209T1 (fr)
DK (3) DK2710039T3 (fr)
EA (3) EA039905B1 (fr)
ES (3) ES2873837T3 (fr)
FR (1) FR22C1032I2 (fr)
HR (3) HRP20190640T1 (fr)
HU (4) HUE054437T2 (fr)
IL (4) IL229431B (fr)
LT (4) LT3662932T (fr)
MX (3) MX370749B (fr)
NL (1) NL301181I2 (fr)
NZ (1) NZ733060A (fr)
PE (2) PE20180502A1 (fr)
PH (1) PH12018500521A1 (fr)
PL (3) PL3662932T3 (fr)
PT (3) PT3495392T (fr)
RS (3) RS58621B1 (fr)
SG (2) SG194938A1 (fr)
SI (3) SI2710039T1 (fr)
TR (1) TR201904088T4 (fr)
TW (4) TWI646111B (fr)
WO (1) WO2012162243A2 (fr)
ZA (1) ZA201308637B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115333B (en) 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
WO2012162243A2 (fr) * 2011-05-20 2012-11-29 Alderbio Holdings Llc Compositions comprenant des anticorps anti-cgrp et leur utilisation
WO2012162253A2 (fr) 2011-05-20 2012-11-29 Alderbio Holdings Llc Utilisation d'anticorps ou de fragments d'anticorps anti-cgrp ou anti-cgrp-r dans le traitement ou la prévention de formes chroniques et aiguës de la diarrhée
CN108014334B (zh) * 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
EP3754012A1 (fr) 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Purification d'anticorps et contrôle de pureté
MX2016000220A (es) * 2013-07-03 2016-08-18 Alder Biopharmaceuticals Inc Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
TWI721976B (zh) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
KR20180058777A (ko) * 2015-09-24 2018-06-01 테바 파마슈티컬스 인터내셔널 게엠베하 (지속성) 외상후 두통의 예방, 치료 및 감소
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2017132062A1 (fr) * 2016-01-28 2017-08-03 Eli Lilly And Company Anticorps anti-cgrp et leurs utilisations
CN108601833B (zh) 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
KR20190067181A (ko) 2016-09-23 2019-06-14 테바 파마슈티컬스 인터내셔널 게엠베하 군발성 두통의 치료
WO2018160896A1 (fr) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Sélection de patients atteints de céphalées présentant une réponse à des anticorps dirigés contre un peptide lié au gène de la calcitonine
CA3087951A1 (fr) 2018-01-12 2019-07-18 Amgen Inc. Anticorps pac1 et leurs utilisations
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
JP2021518748A (ja) * 2018-02-23 2021-08-05 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
WO2019231800A1 (fr) * 2018-05-31 2019-12-05 Eli Lilly And Company Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations
US10899826B1 (en) * 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (fr) * 2018-12-26 2020-07-01 Life Length S.L. Procédé de mesure de variables associés à un télomère et leurs utilisations pour le diagnostic et/ou le pronostic de maladies associées à un télomère
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
TW202030205A (zh) * 2019-01-08 2020-08-16 美商Ａｌｄｅｒ製藥公司 使用抗cgrp 或抗cgrp-r 抗體治療藥物過度使用性頭痛
US20220144892A1 (en) * 2019-02-28 2022-05-12 Dandi Bioscience Inc. Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
BR112020027063A2 (pt) * 2019-05-02 2021-11-16 H Lundbeck As Tratamento de dor de cabeça com uso de anticorpos anti-cgrp
WO2020239014A1 (fr) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 Anticorps anti cgrp et son utilisation
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
WO2022185224A1 (fr) 2021-03-02 2022-09-09 Mark Hasleton Traitement et/ou réduction de l'apparition de migraine
WO2023026205A1 (fr) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Traitement préventif de la migraine
KR20240049275A (ko) 2021-08-27 2024-04-16 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용한 군발성 두통의 치료
WO2023161526A1 (fr) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg Conjugué constitué de ou comprenant au moins un ss-glucane ou un mannane
CN117586390A (zh) * 2022-08-11 2024-02-23 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5123197A (ja) 1974-08-21 1976-02-24 Hitachi Ltd Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1985000043A1 (fr) * 1983-06-15 1985-01-03 Kingdon Craig R Peptides, compositions pharmaceutiques, genes, vecteurs, organismes hotes, leurs procedes de production et reactifs diagnostiques
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992002551A1 (fr) 1990-08-02 1992-02-20 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
JPH11512396A (ja) 1995-09-05 1999-10-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
CA2264942A1 (fr) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Composes et methodes
ES2314305T3 (es) 1996-09-10 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion.
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (fr) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyle benzamides utiles comme antagonistes du recepteur de peptides lies au gene de la calcitonine
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
WO2000023579A1 (fr) 1998-10-22 2000-04-27 The Regents Of The University Of California Anticorps monoclonal intact de recombinaison a assemblage fonctionnel specifique d'un antigene, et son procede d'obtention
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (fr) 1999-02-23 2000-08-30 Warner-Lambert Company Utilisation d'un analogue de la gabapentine pour la fabrication d'un médicament pour la prevention et le traitement des douleurs viscérales
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
EP2341074A1 (fr) 2000-03-01 2011-07-06 MedImmune, LLC Anticorps reconnaissant la protein f du virus respiratoire syncytial (rsv)
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
JP2005523418A (ja) 2001-11-26 2005-08-04 プロテミックス コーポレイション リミティド 哺乳動物組織で脂質レベルを正常化するための方法及び組成物
WO2003085089A2 (fr) 2002-03-29 2003-10-16 Schering Corporation Anticorps monoclonaux humains anti-interleukine-5 et procedes et compositions les contenant
AU2003239841A1 (en) 2002-05-06 2003-11-17 Grunenthal Gmbh Cgrp binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
HUE032132T2 (en) 2002-06-05 2017-09-28 Bristol Myers Squibb Co Peptide receptor related to calcitonin gene
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
ES2323170T3 (es) 2002-08-12 2009-07-08 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para el tratamiento de la psoriasis.
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN100434440C (zh) 2002-12-02 2008-11-19 阿布格尼克斯公司 针对肿瘤坏死因子的抗体及其用途
CA2921578C (fr) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anticorps anti-ngf et procedes d'utilisation de ces anticorps
ATE509019T1 (de) 2003-03-14 2011-05-15 Merck Sharp & Dohme Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
ATE556060T1 (de) 2003-03-14 2012-05-15 Merck Sharp & Dohme Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
JP4690313B2 (ja) 2003-03-14 2011-06-01 メルク・シャープ・エンド・ドーム・コーポレイション カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
EP1605936B1 (fr) 2003-03-14 2011-07-20 Merck Sharp & Dohme Corp. Antagonistes du recepteur cgrp d'aryl spirohydantoine
WO2004082605A2 (fr) 2003-03-14 2004-09-30 Merck & Co. Inc. Antagonistes des recepteurs du cgrp spirohydantoine anilides bicycliques
CA2522024A1 (fr) 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs de cgrp
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (fr) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
HUE033349T2 (en) 2003-10-22 2017-11-28 Keck Graduate Inst Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy
US20080070239A1 (en) 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
CA2552757A1 (fr) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Procedes permettant d'utiliser le cgrp dans des indications cardiovasculaires et renales
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (fr) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007025212A2 (fr) 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Utilisation de bloqueurs des canaux sodiques pour traiter les douleurs viscerales, ou les douleurs provoquees par un traitement anticancereux
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
GEP20115333B (en) * 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
WO2007076336A1 (fr) * 2005-12-22 2007-07-05 Eli Lilly And Company Traitement de la migraine avec des anticorps anti-cgrp
US9074352B2 (en) 2006-03-27 2015-07-07 John R. Ramun Universal control scheme for mobile hydraulic equipment and method for achieving the same
US20070269868A1 (en) 2006-05-19 2007-11-22 Carvalho Jensen Anne E Culture method for obtaining a clonal population of antigen-specific B cells
EP2029234A1 (fr) 2006-06-08 2009-03-04 Boehringer Ingelheim International GmbH Traitement de troubles gastro-intestinaux avec des antagonistes cgrp
ES2343481T3 (es) 2006-07-21 2010-08-02 Vertex Pharmaceuticals, Inc. Antagonistas del receptor cgrp.
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
NZ581418A (en) 2007-05-21 2012-08-31 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
KR101829776B1 (ko) 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
WO2008144753A2 (fr) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Anticorps anti-tnf alpha et leur utilisation
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
CN106110321A (zh) * 2008-03-04 2016-11-16 莱布瑞斯生物公司 治疗炎性疼痛的方法
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US11214610B2 (en) * 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
WO2012162253A2 (fr) 2011-05-20 2012-11-29 Alderbio Holdings Llc Utilisation d'anticorps ou de fragments d'anticorps anti-cgrp ou anti-cgrp-r dans le traitement ou la prévention de formes chroniques et aiguës de la diarrhée
WO2012162243A2 (fr) 2011-05-20 2012-11-29 Alderbio Holdings Llc Compositions comprenant des anticorps anti-cgrp et leur utilisation
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
KR20180058777A (ko) 2015-09-24 2018-06-01 테바 파마슈티컬스 인터내셔널 게엠베하 (지속성) 외상후 두통의 예방, 치료 및 감소
WO2018160896A1 (fr) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center Sélection de patients atteints de céphalées présentant une réponse à des anticorps dirigés contre un peptide lié au gène de la calcitonine
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
WO2018236873A1 (fr) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College Méthodes et compositions pour le traitement d'une infection microbienne
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
TW202030205A (zh) 2019-01-08 2020-08-16 美商Ａｌｄｅｒ製藥公司 使用抗cgrp 或抗cgrp-r 抗體治療藥物過度使用性頭痛
SG11202106766SA (en) 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
TWI646111B (zh) 2019-01-01
HRP20210777T1 (hr) 2021-06-25
EP3495392A1 (fr) 2019-06-12
CA2836649A1 (fr) 2012-11-29
AU2019226231A1 (en) 2019-09-26
CN108424452B (zh) 2021-08-03
IL229431A0 (en) 2014-01-30
NZ717570A (en) 2018-09-28
US10533048B2 (en) 2020-01-14
AU2017203890B2 (en) 2019-06-06
CA2836649C (fr) 2020-06-23
CL2013003336A1 (es) 2014-06-06
TWI719869B (zh) 2021-02-21
CN107602700B (zh) 2021-12-17
US10189895B2 (en) 2019-01-29
IL229431B (en) 2018-10-31
KR20140042819A (ko) 2014-04-07
HRP20211395T1 (hr) 2021-12-10
FR22C1032I1 (fr) 2022-09-09
US20210047391A1 (en) 2021-02-18
BR112013029932A2 (pt) 2017-01-31
SI2710039T1 (sl) 2019-05-31
EA031065B1 (ru) 2018-11-30
MX370749B (es) 2019-12-20
DK3495392T3 (da) 2021-09-13
CN108373502A (zh) 2018-08-07
US20190211085A1 (en) 2019-07-11
TWI685505B (zh) 2020-02-21
JP2014517699A (ja) 2014-07-24
PT2710039T (pt) 2019-04-23
TW201936642A (zh) 2019-09-16
HUE044062T2 (hu) 2019-09-30
US9745373B2 (en) 2017-08-29
KR102128627B1 (ko) 2020-06-30
TW202033559A (zh) 2020-09-16
US20190092842A1 (en) 2019-03-28
NL301181I1 (fr) 2022-06-15
CL2018001452A1 (es) 2018-08-10
ES2893073T3 (es) 2022-02-07
ES2873837T3 (es) 2021-11-04
SG10201604040PA (en) 2016-07-28
JP6282584B2 (ja) 2018-02-21
CN103748111A (zh) 2014-04-23
CA3080000A1 (fr) 2012-11-29
TW201300419A (zh) 2013-01-01
ES2715001T3 (es) 2019-05-31
CN107602700A (zh) 2018-01-19
TR201904088T4 (tr) 2019-05-21
PL2710039T3 (pl) 2019-07-31
JP2019150044A (ja) 2019-09-12
NZ733060A (en) 2022-08-26
US20120294797A1 (en) 2012-11-22
EA201891284A1 (ru) 2018-11-30
EP2710039B1 (fr) 2019-01-09
LT2710039T (lt) 2019-04-25
AU2012258966B2 (en) 2017-03-09
US10066009B2 (en) 2018-09-04
CA3079978A1 (fr) 2012-11-29
ZA201308637B (en) 2022-11-30
EP3662932B1 (fr) 2021-04-07
US10214582B2 (en) 2019-02-26
US20180215813A1 (en) 2018-08-02
CN103748111B (zh) 2018-04-27
US10208112B2 (en) 2019-02-19
AU2019226231B2 (en) 2021-06-03
SG194938A1 (en) 2013-12-30
CO6870005A2 (es) 2014-02-20
NL301181I2 (nl) 2022-11-24
PL3495392T3 (pl) 2021-12-13
US20180215816A1 (en) 2018-08-02
JP6527563B2 (ja) 2019-06-05
HUS2200031I1 (hu) 2022-07-28
WO2012162243A3 (fr) 2013-01-17
PH12018500521A1 (en) 2019-04-15
LT3662932T (lt) 2021-06-10
PT3662932T (pt) 2021-05-14
MX2013013535A (es) 2015-08-20
LT3495392T (lt) 2021-09-27
EP3495392B1 (fr) 2021-08-18
IL268464A (en) 2019-09-26
CN107586338B (zh) 2021-09-17
EA201592042A1 (ru) 2016-03-31
PT3495392T (pt) 2021-09-22
EA039905B1 (ru) 2022-03-25
PE20180502A1 (es) 2018-03-09
TWI692485B (zh) 2020-05-01
JP6952736B2 (ja) 2021-10-20
NZ618637A (en) 2016-03-31
SI3662932T1 (sl) 2021-08-31
TW201811835A (zh) 2018-04-01
AU2017203890A1 (en) 2017-06-29
AR118605A2 (es) 2021-10-20
IL261927A (en) 2018-10-31
HUE054437T2 (hu) 2021-09-28
CY1124209T1 (el) 2022-05-27
MX2019008185A (es) 2019-09-09
MX2019015745A (es) 2020-02-13
HRP20190640T1 (hr) 2019-05-31
US11111289B2 (en) 2021-09-07
DK2710039T3 (en) 2019-04-01
CN107586338A (zh) 2018-01-16
CL2017001379A1 (es) 2017-12-29
WO2012162243A2 (fr) 2012-11-29
SI3495392T1 (sl) 2021-11-30
IL268464B (en) 2020-10-29
EP4115905A1 (fr) 2023-01-11
CN108424452A (zh) 2018-08-21
CY1124515T1 (el) 2022-07-22
EA201301295A1 (ru) 2014-04-30
AP2013007259A0 (en) 2013-11-30
AU2012258966C1 (en) 2022-02-03
EP3662932A1 (fr) 2020-06-10
IL261927B (en) 2019-11-28
US20180215814A1 (en) 2018-08-02
DK3662932T3 (da) 2021-05-17
JP2018038391A (ja) 2018-03-15
PE20141787A1 (es) 2014-12-07
US20180215815A1 (en) 2018-08-02
AR086516A1 (es) 2013-12-18
RS58621B1 (sr) 2019-05-31
EP2710039A2 (fr) 2014-03-26
US20170174754A1 (en) 2017-06-22
PL3662932T3 (pl) 2021-09-06
EP3875115A1 (fr) 2021-09-08
AR123876A2 (es) 2023-01-18
LTPA2022511I1 (fr) 2022-07-11
EP2710039A4 (fr) 2014-11-19
RS62306B1 (sr) 2021-09-30
US10179809B2 (en) 2019-01-15
CN108373502B (zh) 2022-03-22
RS61793B1 (sr) 2021-06-30
BR122022012930B1 (pt) 2023-10-10
HUE055505T2 (hu) 2021-11-29
IL270382B (en) 2020-11-30

Similar Documents

Publication Publication Date Title
FR22C1032I2 (fr) Compositions anti-cgrp et leur utilisation
FR21C1038I2 (fr) 5-fluoro-1h-pyrazolopyridines substituees et leur utilisation
FR20C1068I2 (fr) Anticorps anti-pd-l1 et leur utilisation
BR112013032426A2 (pt) composições probióticas e métodos
BR112013023776A2 (pt) composição e abertura vedada com selante
BR112013017629A2 (pt) laminina-521 recombinante
DK3385421T3 (da) Naturlige nonwoven-materialer
BR112012028633A2 (pt) composição reticulada e artigo
FI20115732A0 (fi) Uusi puhdistinrakenne
DE112012001239A5 (de) Dämpfungseinrichtung
FR2989572B1 (fr) Sparadrap et son utilisation
DE112012000756A5 (de) Dämpfungseinrichtung
FR2980364B1 (fr) Nanoemulsions et leur utilisation comme agents de contraste
BR112013019707A2 (pt) métodos e composições antinematóides
CO6990712A2 (es) Combinación farmacéutica antineuritica y composiciones
FR2989557B1 (fr) Nouvelles compositions alimentaires et leur mode de realisation
FR2970596B1 (fr) Contacteur et interrupteur
ES1073847Y (es) Motocultivador simplificado y aligerado